ReviewMedicina (Kaunas, Lithuania)2018
Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer.
Review in Medicina (Kaunas, Lithuania), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 73 citations in OpenAlex.
- Diagnostic and Prognostic Significance of Chemokines in Head and Neck Cancers: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Transcriptome and m6A epitranscriptome profiling reveal CCL20 as a key mediator of inflammation in Staphylococcus aureus-induced bovine mastitis.BMC microbiology · 2026Article
- Machine learning and bioinformatics framework integration reveal potential characteristic genes related to immune cell infiltration in post-traumatic stress disorder.Scientific reports · 2025Article
- Validation of CCL20-driven CAR-γδ T secreting PD-1 blockade with enhanced trafficking into solid tumor.iScience · 2025Article
- Loss ofOncotarget · 2025Article
- Article
- Mechanisms of host-bacterial interactions duringFrontiers in veterinary science · 2025Article
- Article
- Chemokines and their receptors in oral squamous cell carcinoma: mechanisms, clinical significance, and therapeutic implications.Frontiers in immunology · 2025Review
- Progress of CCL20-CCR6 in the airways: a promising new therapeutic target.Journal of inflammation (London, England) · 2024Review
- Distinct RORγt-dependent Th17 immune responses are required for autoimmune pathogenesis and protection against bacterial infection.Cell reports · 2024Article
- Structural basis for CCR6 modulation by allosteric antagonists.Nature communications · 2024Article
- Exploring the immune landscape and drug prediction of an M2 tumor-associated macrophage-related gene signature in EGFR-negative lung adenocarcinoma.Thoracic cancer · 2024Article
- Review
- Identification of the Binding Epitope of an Anti-Mouse CCR6 Monoclonal Antibody (CAntibodies (Basel, Switzerland) · 2023Article
- CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases.Antibodies (Basel, Switzerland) · 2023Review
- Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma.International journal of molecular sciences · 2023Article
- PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway.Signal transduction and targeted therapy · 2023Article
- Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer.Cell reports. Medicine · 2023Article
- Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prototypical functions of the chemokine receptor CCR6 include immune regulation by maneuvering cell chemotaxis and selective delimiting of the pro-inflammatory T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.